Response Letter to "Letter: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China"

被引：0
|
作者：
Guan, Haijing [1 ]
Sheng, Yanan [2 ]
Guo, Wanjie [3 ]
Han, Sheng [3 ]
Shi, Luwen [1 ]
机构：
[1] Peking Univ, Sch Pharmaceut Sci, Beijing, Peoples R China
[2] Peking Univ, China Ctr Hlth Econ Res, Beijing, Peoples R China
[3] Peking Univ, Int Res Ctr Med Adm, Beijing, Peoples R China
来源：
ADVANCES IN THERAPY | 2020年 / 37卷 / 02期
关键词：
Alectinib; ALK; China; Cost-Effectiveness; NSCLC; CRIZOTINIB;
D O I：
10.1007/s12325-019-01202-2
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
引用
收藏
页码：971 / 972
页数：2
相关论文
共 50 条
  • [41] FDA Approval: Alectinib for the Treatment of Metastatic, ALK-Positive Non-Small Cell Lung Cancer Following Crizotinib
    Larkins, Erin
    Blumenthal, Gideon M.
    Chen, Huanyu
    He, Kun
    Agarwal, Rajiv
    Gieser, Gerlie
    Stephens, Olen
    Zahalka, Eias
    Ringgold, Kimberly
    Helms, Whitney
    Shord, Stacy
    Yu, Jingyu
    Zhao, Hong
    Davis, Gina
    McKee, Amye E.
    Keegan, Patricia
    Pazdur, Richard
    CLINICAL CANCER RESEARCH, 2016, 22 (21) : 5171 - 5176
  • [42] Enteral administration of alectinib for ALK-positive non-small cell lung cancer in an elderly patient A case report
    Thomas, Quentin Dominique
    Pautas, Marie
    Guilhaume, Marie-Noelle
    Fiteni, Frederic
    Ge, Tony
    Girard, Nicolas
    MEDICINE, 2021, 100 (43) : E27611
  • [43] Future options for ALK-positive non-small cell lung cancer
    Iacono, Daniela
    Chiari, Rita
    Metro, Giulio
    Bennati, Chiara
    Bellezza, Guido
    Cenci, Matteo
    Ricciuti, Biagio
    Sidoni, Angelo
    Baglivo, Sara
    Minotti, Vincenzo
    Crino, Lucio
    LUNG CANCER, 2015, 87 (03) : 211 - 219
  • [44] Brigatinib as a treatment of ALK-positive non-small cell lung cancer
    De Carlo, Elisa
    Stanzione, Brigida
    Del Conte, Alessandro
    Revelant, Alberto
    Bearz, Alessandra
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2021, 6 (05): : 299 - 305
  • [45] CNS activity of ensartinib in ALK-positive non-small cell lung cancer patients
    Horn, Leora
    Reckamp, Karen L.
    Patel, Sandip
    Blumenschein, George
    Neal, Joel W.
    Gitlitz, Barbara
    Waqar, Saiama
    Oxnard, Geoffrey
    Brzezniak, Christina
    Dukart, Gary
    Tan, Fenlai
    Harrow, Kimberly
    Liang, Chris
    Gibbons, James
    Wakelee, Heather A.
    CANCER RESEARCH, 2017, 77
  • [46] Brigatinib for the treatment of ALK-positive advanced non-small cell lung cancer patients
    Passaro, A.
    Prelaj, A.
    Pochesci, A.
    Spitaleri, G.
    Rossi, G.
    Del Signore, E.
    Catania, C.
    de Marinis, F.
    DRUGS OF TODAY, 2017, 53 (08) : 435 - 446
  • [47] ALK rearrangement testing and treatment patterns for patients with ALK-positive non-small cell lung cancer
    Guerin, Annie
    Sasane, Medha
    Zhang, Jie
    Macalalad, Alexander R.
    Galebach, Philip
    Jarvis, John
    Kageleiry, Andrew
    Culver, Kenneth
    Wu, Eric Q.
    Wakelee, Heather
    CANCER EPIDEMIOLOGY, 2015, 39 (03) : 307 - 312
  • [48] Successful treatment of crizotinib-induced dysgeusia by switching to alectinib in ALK-positive non-small cell lung cancer
    Koizumi, Tomonobu
    Fukushima, Toshirou
    Tatai, Toshiharu
    Kobayashi, Takashi
    Sekiguchi, Nodoka
    Sakamoto, Akiyuki
    Sasaki, Shigeru
    LUNG CANCER, 2015, 88 (01) : 112 - 113
  • [49] A pregnant patient with ALK-positive non-small cell lung cancer treated with alectinib: A case report and review of the literature
    De Smedt, Fabian
    Dessy, Frederique
    Carestia, Luciano
    Baldin, Pamela
    Nana, Frank Aboubakar
    Clapuyt, Philippe
    Boon, Veronique
    Amant, Frederic
    Gziri, Mina Mhallem
    ONCOLOGY LETTERS, 2023, 25 (02)
  • [50] Response Profile of Non-Small Cells Lung Cancer with ALK Positive Treated with Alectinib
    Sanchez Rios, C. P.
    Martinez Herrera, J. F.
    Alatorre Alexander, J.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (11) : S1189 - S1190
12345